IGCS and Eisai welcomes you to view Precision in Endometrial Cancer: Personalized Treatment Strategies for pMMR and dMMR Endometrial Cancer Industry Supported Symposium presented at the IGCS 2025 Annual Global Meeting in Cape Town, South Africa. This interactive 90-minute symposium will explore the evolving treatment landscape in endometrial cancer, focusing on the distinctions between dMMR and pMMR disease. Faculty will provide expert insights on current treatment paradigms, including immunotherapy, chemotherapy, and novel combinations. Through integrated patient case discussions, the session will highlight how molecular profiling drives treatment selection, the importance of toxicity management, and strategies for sequencing therapies across patient subtypes. The session will conclude with forward-looking perspectives on addressing data gaps and improving outcomes. Learning Objectives: By the end of this session, participants will be able to: 1. Differentiate endometrial cancer across molecular classifications in terms of biology, clinical behavior, and treatment outcomes. 2. Evaluate current evidence and clinical considerations for treatment of, primary advanced and recurrent endometrial cancer. 3. Discuss therapeutic sequencing strategies in advanced/recurrent endometrial cancer, especially in the context of disease progression. 4. Apply real-world patient case scenarios to guide treatment decisions, manage toxicities, and address gaps in sequencing data.
New Presentation as of February 2026!
Decoding Endometrial Cancer: The Role of Molecular Profiling
Presenter: Alexander B. Olawaiye, MD, University of Pittsburgh, USA
 |
Dr. Olawaiye is the Vice Chair for DEI at the Department of Obstetrics, Gynecology and Reproductive Sciences. He is director of gynecologic cancer research at Magee-Women’s Hospital of the University of Pittsburgh Medical Center and has overseen multiple clinical research projects. He is also the GOG Foundation, Inc. principal investigator for the University of Pittsburgh Cancer Institute and in this role has collaborated with multiple clinical scientists across the country to conduct phases I, II and III studies. As well as a co-principal investigator on the University of Pittsburgh ovarian cancer SPORE program. Dr. Olawaiye also studies chemotherapeutic agents and their complications, along with mentoring many younger clinicians at the beginning of their academic careers.
|
Attended previous IGCS webinars? If you have attended IGCS webinars in the past, you may already have an IGCS account and creating a new account is not required. If unsure of your login information, you may reset your information by selecting "Forgot Password" at login or contact education@igcs.org.
If you have questions or need assistance, contact education@igcs.org.